Uncategorised - European Medical Journal

chronic urticaria treatments

Patient Preferences in Chronic Urticaria Treatments

The review revealed that patients consistently prioritise rapid symptom relief, preferably within two weeks, alongside long-term control of hives, itching, and swelling.

blood pressure diet

Rethinking Food Insecurity Solutions for Blood Pressure

A new clinical trial shows food subsidies are more effective than meal boxes in supporting a healthy blood pressure diet.

Roche breaks world record for human genome sequencing

Roche has set a new Guinness World Record for the fastest DNA sequencing of a human genome, marking a major milestone in genomic innovation.

EACS 2025: Low Risk of HBV Reactivation After Tenofovir Withdrawal in People With HIV

EACS 2025 study shows minimal HBV reactivation after stopping tenofovir in people with HIV, supporting safe use of tenofovir-sparing ART.

Patient performing six-minute walking test after pancreatic surgery in hospital corridor

Six-Minute Walk Test Validates Pancreatic Surgery Recovery

The six-minute walking test offers an objective, low-cost assessment of postoperative recovery after pancreatic surgery.

Scientists Link Father’s COVID-19 Infection to Anxiety in Offspring

Scientists Link Father’s COVID-19 Infection to Anxiety in Offspring

A new study shows paternal SARS-CoV-2 infection changes sperm RNA and increases anxiety-like behaviour in offspring, revealing intergenerational effects.

Shifting the Silence in Pulmonary Fibrosis

Pulmonary fibrosis remains one of the most challenging respiratory diseases – often underdiagnosed, undertreated, and misunderstood…

gout flares after stroke concept with inflamed joint

Gout Flares After Stroke Rise in First Week

Gout flares affect one in twenty stroke patients within a week, often the paretic limb, unveiling undiagnosed hyperuricemia.

EACS 2025: Once-Weekly HIV Pill Maintains Viral Suppression for 96 Weeks

New EACS data show once-weekly islatravir and lenacapavir maintain HIV viral suppression for 96 weeks with no resistance or major side effects.

Close-up of azelastine nasal spray used for SARS-CoV-2 prevention

Azelastine Nasal Spray Shows Preventive Benefit

Azelastine nasal spray reduced PCR-confirmed SARS-CoV-2 infections versus placebo in a Phase II randomized trial in adults.